We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The activity-based cost of drug-susceptibility test of Mycobacterium tuberculosis through Kit SIRE Nitratase<sup>®</sup> Plastlabor.
- Authors
de Almeida, Isabela; da Silva, Suely; Junior, Haliton; Figueredo, Lida; Soares, Valéria; Carvalho, Wânia; Kritski, Afrânio; da Costa Fiori, Maria; de Miranda, Silvana
- Abstract
Background: Drug-resistant tuberculosis (TB) is an ongoing health threat, and the greatest challenge to adequate control of TB in many countries lies in the lack of proper laboratory drug-susceptibility test. The aim of this study was to evaluate the activity-based costs (ABC) of Kit SIRE Nitratase® (Kit SIRE) and compare its values with the conventional drug-susceptibility test. Methods: The ABC was calculated for three different approaches: Kit SIRE (clinical samples and cultures), proportion methods in Lowenstein Jensen (PM-LJ), and the Bactec™ MGIT™ 960 system based on Mycobacterial Research Laboratory's routine. Results: The ABC of Kit SIRE from cultures was US$ 148.54, while from clinical samples was US$ 136.12. In the case of conventional tests, the ABC of Bactec™ MGIT™ 960 was US$ 227.63 and of the PM-LJ was US$ 132.64. The Kit SIRE has a lower ABC when clinical samples are used instead of cultures. Compared to conventional tests, the ABC is similar to the PM-LJ and lower the Bactec™ MGIT™ 960. Conclusion: The Kit SIRE should be used as a screening method in clinical specimens and in culture for laboratories that do not have Bactec™ MGIT™ 960. Therefore, it can be incorporated into the routine of laboratories in countries with low resources and a high burden of TB and drug-resistant TB.
- Publication
International Journal of Mycobacteriology, 2020, Vol 9, Issue 1, p24
- ISSN
2212-5531
- Publication type
Article
- DOI
10.4103/ijmy.ijmy_8_20